Role for Chinese herbals plus antipsychotic drugs

6 May 2007

A study published in the May issue of the British Journal of Psychiatry suggests that combining traditional Chinese medicine with western antispychotic medication is beneficial in the treatment of schoziphrenia. The seven studies reviewed were identified from the Cochrane Schizophrenia Group's register of trials, as well as a range of Chinese databases.

The authors of the study comment that the results are "broadly encouraging." They suggest that combination treatment might be beneficial in terms of certain measures of improvement in schizophrenia, although results are based on only two small studies of a total of 103 people. Medium-term data on the negative symptoms of schizophrenia, such as withdrawal, were more robust, with three studies of a total of 741 people favoring the herbal plus antipsychotic combination group.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight